Allison Dorval is Chief Financial Officer of Verve Therapeutics, Inc.. Currently has a direct ownership of 4,060 shares of VERV, which is worth approximately $24,075. The most recent transaction as insider was on Nov 29, 2023, when has been sold 554 shares (Common Stock) at a price of $11.45 per share, resulting in proceeds of $6,343. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 4.06K
0% 3M change
85.73% 12M change
Total Value Held $24,075

Allison Dorval Transaction History

Date Transaction Value Shares Traded Shares Held Form
Nov 29 2023
SELL
Open market or private sale
$6,343 $11.45 p/Share
554 Reduced 12.01%
4,060 Common Stock
Nov 29 2023
BUY
Exercise of conversion of derivative security
-
1,875 Added 28.9%
4,614 Common Stock
Nov 29 2022
SELL
Open market or private sale
$12,243 $22.1 p/Share
554 Reduced 20.22%
2,186 Common Stock
Nov 29 2022
BUY
Exercise of conversion of derivative security
-
1,875 Added 40.63%
2,740 Common Stock

Also insider at

VYGR
Voyager Therapeutics, Inc. Healthcare
PBYI
PUMA BIOTECHNOLOGY, INC. Healthcare
AVTE
Aerovate Therapeutics, Inc. Healthcare
AD

Allison Dorval

Chief Financial Officer
Cambridge, MA

Track Institutional and Insider Activities on VERV

Follow Verve Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VERV shares.

Notify only if

Insider Trading

Get notified when an Verve Therapeutics, Inc. insider buys or sells VERV shares.

Notify only if

News

Receive news related to Verve Therapeutics, Inc.

Track Activities on VERV